Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $19.7 million.

  • Corcept Therapeutics' Income from Continuing Operations fell 5834.2% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.2 million, marking a year-over-year decrease of 2514.68%. This contributed to the annual value of $141.2 million for FY2024, which is 3304.03% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Income from Continuing Operations of $19.7 million as of Q3 2025, which was down 5834.2% from $35.2 million recorded in Q2 2025.
  • Corcept Therapeutics' Income from Continuing Operations' 5-year high stood at $47.2 million during Q3 2024, with a 5-year trough of $15.8 million in Q1 2023.
  • In the last 5 years, Corcept Therapeutics' Income from Continuing Operations had a median value of $27.8 million in 2024 and averaged $28.2 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Income from Continuing Operations skyrocketed by 8907.43% in 2023, and later plummeted by 5834.2% in 2025.
  • Over the past 5 years, Corcept Therapeutics' Income from Continuing Operations (Quarter) stood at $32.1 million in 2021, then plummeted by 48.2% to $16.6 million in 2022, then soared by 89.07% to $31.4 million in 2023, then dropped by 1.96% to $30.8 million in 2024, then tumbled by 36.09% to $19.7 million in 2025.
  • Its last three reported values are $19.7 million in Q3 2025, $35.2 million for Q2 2025, and $20.5 million during Q1 2025.